2017 American Transplant Congress
The Inhibitory Effect of Plasma on T Cell Activation: Possible Role of Plasma Exchange in Anti Rejection Therapy.
Reduction of lymphocyte proliferation by human plasma has been previously reported. Reduced activation of lymphocytes of patients on immunosuppressive drugs is well documented.Aim: To compare…2017 American Transplant Congress
Renal Transplant Outcomes in Primary FSGS Compared with Other Recipients: A National Review of the Irish Transplant Registry.
Primary focal segmental glomerular sclerosis (p-FSGS) raises specific peri-transplant concerns, one of which is disease recurrence (r-FSGS). We aimed to compare transplant outcomes in patients…2017 American Transplant Congress
Pre-Operative Desensitization for Live Donor Liver Transplantation with Strong Donor-Specific Antibodies.
Background: Presence of strong donor-specific antibodies (DSA) (MFI>4000) likely results in uncomplicated short-term outcome in whole liver transplants due to absorption of DSA by the…2017 American Transplant Congress
Anti-CD25mAb Sparing Immunosuppressive Regimen Suppressed Recurrence of Post-Transplant Focal Segmental Glomerular Sclerosis- A Single Center Experience.
Kidney Transplant Surgery, Sapporo City General Hospital, Sapporo, Japan
INTRODUCTION: The rate of recurrence of primary focal segmental glomerular sclerosis (FSGS) is problematic, because it often results in very early serious urinary protein secretion…2016 American Transplant Congress
Factors Associated with Response to Plasmapheresis in Patients with Recurrent FSGS.
Background:Idiopathic focal segmental glomerulosclerosis (FSGS) is one of the primary glomerular diseases that commonly recurs in renal allograft and is known to be associated with…2016 American Transplant Congress
Donor Specif Antibody (DSA) Kinetics in Patients with Antibody Mediated Rejection (AMR) Treated with Plasmapheresis and Bortezomib.
Backgroud: The best choice to treat AMR is not supported by several evidences, and recently the interest in drugs as Bortezomib has improved. Aim: Evaluted…2016 American Transplant Congress
Postoperative Rebound of Anti-Blood Type Antibodies and Antibody-Mediated Rejection After ABO-Incompatible Living Related Kidney Transplantation – Is Prophylactic Treatment Necessary?
Urology, Tokyo Women's Medical University Hospital, Tokyo, Japan.
PURPOSE: The role of postoperative anti-ABO titers in acute rejection under our current immunosuppressive regimen remains unclear. Some institutions recommend postoperative therapeutic plasma exchange to…2016 American Transplant Congress
Early Posttransplant Complications Following Abo-Incompatible Kidney Transplantation.
Introduction: Many studies or registries particularly in Japan, but also in Western Europe, have shown that long-term results from ABO-incompatible (ABOi) living-kidney transplantation are as…2016 American Transplant Congress
A2 Kidneys into B Recipients: Is Postoperative Anti-A1 Titer Monitoring Useful?
Kidney and Pancreas Transplantation, Vanderbilt University Medical Center, Nashville, TN.
Background: Since the introduction of the new Kidney Allocation System in December 2014, our center implemented a protocol for transplanting A2 kidneys into B recipients…2016 American Transplant Congress
Utilization of Plasmapheresis and High Dose of Immunoglobulins in the Treatment of the High Level of De Novo Donor Specific Antibodies for the Successful Islet Allotransplantation.
Background.Development of donor specific antibodies (DSA) after islet transplantation has been a poor prognostic factor for graft survival, while no intervention is implemented. Here, we…
American Transplant Congress abstracts